Scroll down to learn moreChronic inflammation is robbing the world of productive life and costing us trillions every decade.
60% of deaths worldwide are tragically linked to chronic inflammation
80% of adults over 60 suffer from at least one chronic condition
2.1B people worldwide will be over the age of 60 by 2050
$29.6T will be the expected costs of managing chronic diseases
We are bringing glycans to the world to help make personalized preventative healthcare a reality in the next 10 years.
FOUNDERS
Meet the People Behind GlycanAge
Our vision is driven by a team of dedicated individuals, from our core operational team to our expert longevity specialists and esteemed science advisory board.
Together, we are committed to making glycan-based insights accessible and actionable, empowering individuals to take control of their health.
Gordan Lauc, CSO, Co-Founder
Professor Gordan Lauc is the scientific mind behind GlycanAge. After two decades of pioneering research linking glycans to inflammation and aging, he co-founded the company to bring this powerful science out of the laboratory and directly to the public.
As Chief Scientific Officer, Gordan ensures the scientific validity of the product and leads the ongoing research to uncover new insights into health and longevity.
Nikolina Lauc, CEO, Co-Founder
Nikolina is the driving force behind GlycanAge's mission to empower people to take control of their health. As CEO, she leads the company's strategy, growth, and operations.
Nikolina’s passion lies in translating complex scientific knowledge into an accessible and actionable product that helps people understand their bodies and make better lifestyle choices for a longer, healthier life.
Filip Lauc, CTO, Co-Founder
Filip is the architect of the GlycanAge digital platform. As CTO, he leads the technology and product teams responsible for transforming complex biological data into the personal, intuitive insights our customers receive.
Filip is dedicated to building a seamless user experience that makes understanding and improving your biological age straightforward and engaging.
Cameron Reynolds
Chairman of the Board
Founder and CEO of Volition RX, an experienced executive in a wide range of fields, including biotechnology.
Dr. Diane Seimetz
Board Member
Drug development and regulatory expert with 22+ years experience in the biopharmaceutical sector.
Short term goals (next 12-18 months):
Long term goals (18+ months):
GlycanAge Seed Round
19 Feb 2024GlycanAge has raised $4.2M in seed funding, marking a major milestone in our mission to bring glycan-based biological age testing into everyday clinical practice. The investment enables expanded laboratory capacity and deeper scientific validation. It also accelerates development of next-generation products that will power the future of personalised longevity.
Collaboration with Clinique La Prairie
10 Jul 2025A flagship partnership has launched at Clinique La Prairie, the world-renowned medical spa in Montreux. We implemented a tailored white-label product, an exclusive chronic inflammation score and a faster turnaround time to support their elite longevity programs. This collaboration showcases how glycan-based insights elevate high-end personalised health.
Expansion into the Chinese Market
30 May 2025GlycanAge has entered the Chinese market through a new distribution agreement with GlycanCode Biotech. The partnership enables local laboratories to perform glycan analysis directly, bringing our technology closer to clinicians and consumers. This model sets the foundation for scalable expansion across one of the world’s most dynamic longevity markets.
MoU Signed with KACST
30 Oct 2025A Memorandum of Understanding has been signed with King Abdulaziz City for Science and Technology, Saudi Arabia’s leading national research institution. The collaboration supports localisation of glycan analysis technology and contributes to the Kingdom’s Vision 2030 goals. Together we aim to advance preventive, data-driven and personalised healthcare across the region.
AI Interpretation Tool Launched
15 Sep 2025The AI Interpretation Tool has officially launched, offering real-time analysis powered by glycan science. Trained on over 200,000 samples and 300+ publications, it delivers personalised insights on biological age and health optimisation. Designed for 24/7 use, it brings expert-level interpretation directly to practitioners and individuals.
How is GlycanAge different from genetic or epigenetic tests?
Who are your competitors?
Why hasn’t big pharma or academia led this field?
What’s your regulatory position?
What’s your IP position?
STAY UPDATED
Join Our Mailing List
Be the first one to hear about our milestones, key insights, company news, and investment opportunities.